141 related articles for article (PubMed ID: 33393940)
1. Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers.
Thangavel Mahalingam V; Kaliappan I; Rajappan Chandra SK; George M; Ramasamy MK; Sabarathinam S; Govind Prasad D
Curr Ther Res Clin Exp; 2021; 94():100619. PubMed ID: 33393940
[TBL] [Abstract][Full Text] [Related]
2. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
Yu RZ; Geary RS; Flaim JD; Riley GC; Tribble DL; vanVliet AA; Wedel MK
Clin Pharmacokinet; 2009; 48(1):39-50. PubMed ID: 19071883
[TBL] [Abstract][Full Text] [Related]
3. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.
Patel CG; Li L; Girgis S; Kornhauser DM; Frevert EU; Boulton DW
Clin Pharmacol; 2011; 3():13-25. PubMed ID: 22287853
[TBL] [Abstract][Full Text] [Related]
4. Comparative inhibitory potential of selected dietary bioactive polyphenols, phytosterols on CYP3A4 and CYP2D6 with fluorometric high-throughput screening.
Vijayakumar TM; Kumar RM; Agrawal A; Dubey GP; Ilango K
J Food Sci Technol; 2015 Jul; 52(7):4537-43. PubMed ID: 26139922
[TBL] [Abstract][Full Text] [Related]
5. Interaction potential of Trigonella foenum graceum through cytochrome P450 mediated inhibition.
Ahmmed SM; Mukherjee PK; Bahadur S; Kar A; Mukherjee K; Karmakar S; Bandyopadhyay A
Indian J Pharmacol; 2015; 47(5):530-4. PubMed ID: 26600643
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
8. CYP450 mediated inhibition potential of Swertia chirata: An herb from Indian traditional medicine.
Ahmmed SM; Mukherjee PK; Bahadur S; Harwansh RK; Kar A; Bandyopadhyay A; Al-Dhabi NA; Duraipandiyan V
J Ethnopharmacol; 2016 Feb; 178():34-9. PubMed ID: 26657265
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
10. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Oct; 68(4):384-90. PubMed ID: 11061578
[TBL] [Abstract][Full Text] [Related]
11. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Hatorp V; Hansen KT; Thomsen MS
J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay.
Ab Rahman NS; Abd Majid FA; Abd Wahid ME; Zainudin AN; Zainol SN; Ismail HF; Wong TS; Tiwari NK; Giri S; Bhargava V
Drug Metab Lett; 2018; 12(1):62-67. PubMed ID: 29542427
[TBL] [Abstract][Full Text] [Related]
13. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 inhibitory potential and RP-HPLC standardization of trikatu--a Rasayana from Indian Ayurveda.
Harwansh RK; Mukherjee K; Bhadra S; Kar A; Bahadur S; Mitra A; Mukherjee PK
J Ethnopharmacol; 2014 May; 153(3):674-81. PubMed ID: 24690772
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A.
Schmitt-Hoffmann AH; Roos B; Sauer J; Spickermann J; Maares J; Schoetzau A; Meyer I
Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():24-8. PubMed ID: 21443601
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays.
Xing Y; Yu Q; Zhou L; Cai W; Zhang Y; Bi Y; Zhang Y; Fu Z; Han L
Phytomedicine; 2023 Apr; 112():154710. PubMed ID: 36805481
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins.
Zhang B; Zhan G; Fang Q; Wang F; Li Y; Zhang Y; Zhao L; Zhang G; Li B
Mol Med Rep; 2019 Nov; 20(5):4713-4722. PubMed ID: 31545497
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
Backman JT; Kyrklund C; Kivistö KT; Wang JS; Neuvonen PJ
Clin Pharmacol Ther; 2000 Aug; 68(2):122-9. PubMed ID: 10976543
[TBL] [Abstract][Full Text] [Related]
20. Metabolism-mediated interaction potential of standardized extract of
Bahadur S; Mukherjee PK; Milan Ahmmed SK; Kar A; Harwansh RK; Pandit S
Indian J Pharmacol; 2016; 48(5):576-581. PubMed ID: 27721546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
